Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Anglo-French Drugs & Industries reports standalone net loss of Rs 3…

Anglo-French Drugs & Industries reports standalone net loss of Rs 3.35 crore in the December 2023 quarter

13 Feb 2024

Add as preferred source
Key Takeaways

  • Strong Performance:

    • Witnessed a 36.78% Sales Increase.

  • Financial Stability:

    • Substantial Reduction in Net Loss.

  • Operational Efficiency Boost:

    • Enhanced OPM Reflects Improved Efficiency.

  • Strong Performance:

    • Witnessed a 36.78% Sales Increase.

  • Financial Stability:

    • Substantial Reduction in Net Loss.

  • Operational Efficiency Boost:

    • Enhanced OPM Reflects Improved Efficiency.

Anglo French Drugs and Industries Unlisted Shares

Anglo French Drugs and Industries

-0.18%

Expert Analysis

Anglo-French Drugs & Industries reports standalone Robust growth: Sales Soar by 36.78% and Net Loss declines significantly for the quarter ended Dec 23

Expert Analysis:

  • Sales Surge:

    • Impressive 36.78% Growth to Rs 25.66 crore.

  • Financial Turnaround:

    • Net Loss Narrows from Rs 7.06 crore from the previous quarter ended Dec 22 to Rs 3.35 crore for the quarter ended Dec 23.

  • Operational Efficiency:

    • OPM Improves from -38.43% to -10.05%.

Publisher:Business Standard